ClinVar Miner

Submissions for variant NM_000546.5(TP53):c.1040C>T (p.Ala347Val) (rs397516434)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000484420 SCV000572264 uncertain significance not provided 2016-11-11 criteria provided, single submitter clinical testing This variant is denoted TP53 c.1040C>T at the cDNA level, p.Ala347Val (A347V) at the protein level, and results in the change of an Alanine to a Valine (GCC>GTC). This variant has not, to our knowledge, been published in the literature as either a pathogenic germline variant or a benign polymorphism. However, it has been reported as a somatic variant in a rhabdomyosarcoma and a squamous cell carcinoma (Clynick 2015, Maher 2016). While this variant has been shown to have reduced tetramer formation, transactivation activity is comparable to wild type (Kawaguchi 2005). This variant is also reported as having partially functional transactivation in the International Agency for Research on Cancer TP53 database based on functional assays by Kato et al. (2003).TP53 Ala347Val was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, suggesting it is not a common benign variant in these populations. Since Alanine and Valine share similar properties, this is considered a conservative amino acid substitution. TP53 Ala347Val occurs at a position that is conserved in mammals and is located in the teramerization domain and the region of nuclear export signals (Bode 2004, Pessoa 2014). In silico analyses predict that this variant is probably damaging to protein structure and function. Based on currently available evidence, it is unclear whether TP53 Ala347Val is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.
Ambry Genetics RCV000567572 SCV000665067 uncertain significance Hereditary cancer-predisposing syndrome 2017-10-23 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: Insufficient or conflicting evidence

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.